Article

Ikaros DNA-Binding Proteins as Integral Components of B Cell Developmental-Stage-Specific Regulatory Circuits

Lymphocyte Development Group, MRC Clinical Sciences Centre, Imperial College London, Du Cane Road, London W12 0NN, UK.
Immunity (Impact Factor: 19.75). 04/2007; 26(3):335-44. DOI: 10.1016/j.immuni.2007.02.010
Source: PubMed

ABSTRACT Ikaros DNA-binding proteins are critical for the development of lymphocytes and other hematopoietic lineages, but it remains unclear how they cooperate with other regulators of signaling and transcription to achieve ordered gene expression during development. Here, we show that Ikaros proteins regulate the pre-BCR component lambda5 in a stage-specific manner. In pre-BI cells, Ikaros modulated lambda5 expression in competition with the transcriptional activator EBF. This required Ikaros binding to the Igll1 (lambda5) promoter and was abolished either by mutation of the Ikaros DNA-binding domain or by deletion of a single Ikaros site from the Igll1 promoter. At the transition from the pre-BI to pre-BII stage, the expression of the Ikaros family member Aiolos was upregulated and required for the efficient silencing of Igll1. Aiolos expression was controlled by pre-BCR signals via the adaptor protein SLP-65. Thus, pre-BCR signaling regulates Aiolos and the silencing of Igll1 via a developmental-stage-specific feedback loop.

Download full-text

Full-text

Available from: Pierangela Sabbattini, Feb 19, 2014
1 Follower
 · 
140 Views
  • Source
    • "This suggests that not only does Ikaros regulate signaling through lymphocyte receptors, but lymphocyte receptor signaling can also control the expression of Ikaros family members. The pre-BCR-to-Aiolos feedback loop depends on a specific branch of pre-BCR signaling mediated by the adapter adaptor protein SH2-domain-containing leukocyte protein of 65 kDa, SLP65 [20]. The interferon regulatory factors 4 and 8 may mediate between SLP65 and Aiolos [47]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ikaros is the founding member of a family of transcription factors. Ikaros proteins are required for the normal development of lymphocytes and other blood cell lineages, and have an important role in haematopoietic malignancies. Accumulating data link Ikaros to immune receptor rearrangement and signaling, and the balance between proliferation and differentiation of immune cells. The emerging picture is that Ikaros family members are critical for a functional immune system that confers protection against invading pathogens, while minimising the risk of leukaemic transformation, immune pathology, and autoimmunity.
    FEBS letters 09/2010; 584(24):4910-4. DOI:10.1016/j.febslet.2010.09.042 · 3.34 Impact Factor
  • Source
    • "Ikaros family transcription factors – especially Ikaros and Aiolos are required for B cell development to progress ( Thompson et . al , 2007 ) . B and T cell development is arrested in Ikaros - deficient mice with abnormal myelopoeisis ( Wang et . al . , 1996 ) ."
    [Show abstract] [Hide abstract]
    ABSTRACT: B cell lineage ALL represents by far the most frequent malignancy in children and is also common in adults. Despite significant advances over the past four decades, cytotoxic treatment strategies have recently reached a plateau with cure rates at 80 percent for children and 55 percent for adults. Relapse after cytotoxic drug treatment, initial drug-resistance and dose-limiting toxicity are among the most frequent complications of current therapy approaches. For this reason, pathway-specific treatment strategies in addition to cytotoxic drug treatment seem promising to further improve therapy options for ALL patients. In a recent study on 111 cases of pre-B cell-derived human ALL, we found that ALL cells carrying a BCR-ABL1-gene rearrangement lack expression of a functional pre-B cell receptor in virtually all cases. In a proof-of-principle experiment, we studied pre-B cell receptor function during progressive leukemic transformation of pre-B cells in BCR-ABL1-transgenic mice: Interestingly, signaling from the pre-B cell receptor and the oncogenic BCR-ABL1 kinase are mutually exclusive and only "crippled" pre-B cells that fail to express a functional pre-B cell receptor are permissive to transformation by BCR-ABL1.
    Cell cycle (Georgetown, Tex.) 12/2009; 8(23):3874-7. DOI:10.4161/cc.8.23.10035 · 5.01 Impact Factor
  • Source
    • "As mentioned above, noticeably, the Aiolos gene is widely expressing through the normal developmental stage from pro-B cells to mature B cells [7] [8]. Recently, Thompson et al. showed that pre-BCR signaling regulates Aiolos expression via the adaptor protein SLP-65 [17]. In addition, it has been reported that Aiolos is up-regulated in chronic lymphocytic leukemia [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antigen binding to B cell receptor (BCR) of pre-mature B lymphocytes leads to their apoptosis, while binding to BCR of mature B lymphocytes induces their activation and proliferation. The former binding is believed to be a mechanism so as to exclude B cell clones leading to protection from auto-immune diseases. Cross-linking of BCR of pre-mature B cells, including chicken DT40 cells, with anti-immunoglobulin antibody induces their apoptosis. The PMA/ionomycin treatments, which mimic BCR stimulation, are used to study intracellular signal transduction of B lymphocytes. Here, by analyzing the Aiolos-deficient DT40 cell line, Aiolos(-/-), we reveal that the lack of Aiolos accelerates apoptosis of DT40 cells mediated by BCR signaling. Moreover, the Aiolos-deficiency and BCR signaling cooperatively control this apoptosis through dramatically elevated cytochrome c release from mitochondria to cytosol and elevated caspase (caspase-3, 8 and 9) activities, resulting in drastically diminished amounts of ICAD followed by increased DNA fragmentation. Re-expression study reveals that the shorter isoform of Aiolos (Aio-2) controls PMA/ionomycin-mediated apoptosis via up-regulation and down-regulation of the PKCdelta and bak genes, respectively. These findings could be a powerful trigger to resolve molecular mechanisms of negative selection of B lymphocytes and also auto-immune diseases.
    Biochimica et Biophysica Acta 06/2009; 1793(7):1304-14. DOI:10.1016/j.bbamcr.2009.04.016 · 4.66 Impact Factor
Show more